This study is looking at whether a special imaging scan, called a PET-CT, using a substance called Evuzamitide, can help doctors diagnose a heart condition called transthyretin cardiac amyloidosis (ATTR-CA). This is for patients who have had unclear results from standard heart scans but have high levels of a blood marker called TAD1. The main goal is to see if Evuzamitide PET-CT imaging can show signs of ATTR-CA in these patients. If you qualify, you would receive a single injection of Evuzamitide and then have a PET-CT scan. Researchers will then follow up with you for about 28 days to check on your safety and gather more information. The study aims to enroll up to 25 participants.

Study design

This is an observational study involving up to 25 participants. It is designed to evaluate the ability of 124I-evuzamitide PET-CT imaging to resolve the diagnosis of ATTR-CA.

What's involved

You would receive a single intravenous injection of Evuzamitide, followed by a PET-CT scan approximately 4 hours later. There will be a follow-up period of approximately 28 days to monitor your safety and collect additional clinical information.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for approximately 28 days after the imaging to monitor safety and collect additional clinical information.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.